Jon Yewdell returns to TWiV to discuss how antibodies are made, vaccination against SARS-CoV-2, antigenic variation of the virus, booster shots, and more.
In COVID-19 clinical update #98, Daniel Griffin reviews COVID-19 in South Africa, recognition of Omicron by ancestral T cells, booster effectiveness against disease, infection and vaccination in pregnant women, early Remdesivir to prevent progression to severe disease, management of hospitalized adults, Tocilizumab in hospitalized patients, vaccination and long COVID, and the true toll of the pandemic.
TWiV 855: T time with Alessandro Sette
- January 20, 2022
- Tagged as: coronavirus, COVID-19, delta, immunological memory, Omicron, pandemic, SARS-CoV-2, t cells, Vaccine, variants of concern, viral, virology, virus
Alessandro Sette returns to TWiV to discuss the observation that SARS-CoV-2 vaccination induces T cells that are able to cross-recognize variants Alpha to Omicron.
In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for thromboprophylaxis.
In COVID-19 clinical update #96, Daniel Griffin reviews Omicron in South Africa, rapid antigen tests, viral coinfections, isolation and quarantine, saliva preferred for Omicron, risk factors for severe disease in vaccinated, Paxlovid dosing, and long COVID.
In COVID-19 clinical update #95, Daniel Griffin discusses new CDC guidelines for isolation and quarantine, EUA for Molnupiravir, children and COVID, vaccine safety in 5-11 year olds, Omicron outbreaks in Nebraska and Denmark, Baylor’s COVID vaccine, and COVID-OUT for ivermectin.
In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients.
In COVID-19 clinical update #93, Dr. Griffin summarizes Omicron fitness, S-gene target failure, monoclonal efficacy against Omicron, vaccination, monoclonals, and disease in children, persistence of memory B cells in the elderly, infection and vaccine induced immunity, protection against severe illness and death by a third mRNA vaccine dose, high flow oxygen versus intubation, and therapeutic anticoagulation.
TWiV 839: The long and the short of it: get vaccinated
- December 9, 2021
- Tagged as: coronavirus, COVID-19, mRNA vaccine, Omicron, pandemic, SARS-CoV-2, vaccine dose schedule, variant of concern, viral, virology, virus, viruses
TWiV reviews the impact of vaccination on SARS-CoV-2, the latest information on Omicron, West Nile virus transmission by organ transplantation, and why a 16 week interval between doses of BNT162b2 vaccine is better than a shorter interval.
TWiV 838: The magic virus bus
- December 5, 2021
- Tagged as: biobus, coronavirus, COVID-19, Omicron, pandemic, SARS-CoV-2, variant of concern, viral, virology, virus, virus hunters, viruses
The New York City Virus Hunters join TWiV to reveal how local students engage in safe virus surveillance and conduct science research right in their neighborhoods, followed by an update on variant of concern Omicron.